Key points are not available for this paper at this time.
This pooled cross-sectional study explores prescribing rates for glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors among US patients with type 1 diabetes.
Li et al. (Wed,) studied this question.